lecozotan lecozotan lecozotan is an investigational drug by wyeth tested for improvement of cognitive functions of alzheimer's disease patients. as of june 2008, the first phase iii clinical trial has been completed. lecozotanidentifiers iupac name 4-cyano-n-propyl]-n-2-pyridinylbenzamide hydrochloride cas number434283-16-6pubchem cid10116877chemspider8292400unii48854otz5ekeggd04683 ychemblchembl372205comptox dashboard (epa)dtxsid20195826 chemical and physical dataformulac28h30cln5o3molar mass520.03 g·mol−13d model (jsmol)interactive image smiles c(cn(c1=cc=cc=n1)c(=o)c2=cc=c(c=c2)c#n)n3ccn(cc3)c4=c5c(=cc=c4)occo5 inchi inchi=1s/c28h29n5o3/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23/h2-12,21h,13-18,20h2,1h3/t21-/m1/s1key:nrpqelcnmadtoz-oaqylsrusa-n (verify) method of action lecozotan is a competitive, selective 5-ht1a receptor antagonist which enhances the potassium-stimulated release of acetylcholine and glutamate.